Approved for ONAPGO is indicated for the treatment of motor fluctuations in adults with advanced Parkinson's disease.. ONAPGO is a non-ergoline dopamine agonist with high in vitro binding affinity for the dopamine D4 receptor, and moderate affinity for the dopamine D2, D3, and D5, and adrenergic α1D, α2B, α2C… Side effects, costs, interactions, manufacturer, and generic alternatives sourced from…
Loading full data from Know Your Drugs Institute…